Mission BioCapital

Comet Therapeutics, established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing novel small-molecule treatments for various diseases, with a focus on orphan neurological disorders. The company's core technology is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism, thereby addressing significant unmet medical needs in these areas.

Mitokinin, Inc. is a biotechnology company based in New York, focused on developing small molecule therapeutics aimed at treating neurodegenerative diseases, particularly Parkinson's disease. The company specializes in medicinal chemistry to create kinetin analogs that optimize the activation of PINK1, a protein involved in cellular health. Mitokinin's compounds are designed to enhance the activity of active-form PINK1 without interfering with its natural regulation. Founded in 2017, the company comprises a team of neuroscientists, chemists, and pharmacologists dedicated to advancing disease-modifying therapies in the healthcare sector.

Redwood Bioscience is a biotechnology company focused on precision protein-chemical engineering to develop optimized biotherapeutics. Established in 2008 and based in Emeryville, California, the company specializes in site-specific modification technology, which addresses the challenges of conjugating biologics with synthetic molecules. This innovative approach enables the creation of homogeneous hybrid biotherapeutics, enhancing the effectiveness of treatments. Redwood Bioscience's methods for optimizing drug conjugates leverage the binding specificity and extended half-life of biologic carriers while incorporating the potency advantages of small molecules and synthetic peptides, positioning the company at the forefront of advancements in antibody-drug conjugates and semi-synthetic biotherapeutics.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.